SK Capital has signed a definitive agreement to acquire Perrigo API, an active pharmaceutical ingredient (API) business of Perrigo Company plc.
As part of the transaction, the parties have agreed to enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The transaction is expected to close during Q4 2017, before which a new trade name will be selected and announced for the business.
Perrigo API is a leading developer and manufacturer of generic APIs and finished dose forms (FDF) with operations primarily located in Israel and supporting functions in US and India. The business has a global customer base and a broad array of products that leverage its specialized manufacturing capabilities and core competency in complex chemistries.
Perrigo API is known for its uncompromising commitment to the highest quality and reliability standards and has an exemplary compliance track record.
Read more: SK Capital acquire Perrigo’s API business
No comments:
Post a Comment